China Biologic Produ
(CBPO)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2020 | 06-2020 | 03-2020 | 12-2019 | 09-2019 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 149,216 | 102,794 | 62,235 | 163,395 | 146,798 |
| Depreciation Amortization | 20,012 | 13,204 | 6,628 | 26,241 | 18,988 |
| Income taxes - deferred | -1,148 | -811 | -55 | -2,437 | -1,856 |
| Accounts receivable | -33,131 | -16,873 | -35,256 | 22,133 | -19,227 |
| Accounts payable and accrued liabilities | 536 | 3,208 | -424 | -1,299 | -2,258 |
| Other Working Capital | -8,845 | 6,341 | -534 | 13,205 | -23,597 |
| Other Operating Activity | 61,853 | 27,607 | 43,149 | 8,104 | 37,579 |
| Operating Cash Flow | $188,493 | $135,470 | $75,744 | $229,342 | $156,427 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 954,309 | 914,518 | 359,723 | 1,522,173 | 1,235,859 |
| PPE Investments | -12,093 | -6,367 | -3,234 | -19,724 | -17,225 |
| Purchase Of Investment | -711,900 | -651,415 | -469,927 | -1,682,444 | -1,253,814 |
| Purchase Sale Intangibles | -2,028 | -683 | -7 | -149 | -2,441 |
| Other Investing Activity | -2,028 | -683 | -7 | -150 | -2,441 |
| Investing Cash Flow | $228,288 | $256,054 | $-113,444 | $-180,144 | $-37,621 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 300 | 300 | N/A | 612 | 455 |
| Common Stock Repurchased | N/A | N/A | N/A | N/A | -110,043 |
| Dividend Paid | -12,285 | -7,303 | N/A | -10,125 | -10,125 |
| Other Financing Activity | 0 | 0 | 0 | -219,957 | -118,949 |
| Financing Cash Flow | $-11,985 | $-7,002 | $N/A | $-229,470 | $-238,662 |
| Exchange Rate Effect | 315 | -1,134 | -1,194 | 3,142 | 1,825 |
| Beginning Cash Position | 161,750 | 161,750 | 161,750 | 338,881 | 338,881 |
| End Cash Position | 566,862 | 545,138 | 122,856 | 161,750 | 220,850 |
| Net Cash Flow | $405,112 | $383,387 | $-38,895 | $-177,130 | $-118,031 |
| Free Cash Flow | |||||
| Operating Cash Flow | 188,493 | 135,470 | 75,744 | 229,342 | 156,427 |
| Capital Expenditure | -12,100 | -6,370 | -3,235 | -24,287 | -18,821 |
| Free Cash Flow | 176,393 | 129,100 | 72,509 | 205,055 | 137,606 |